Weight Loss Competition Heats Up In Britain, Online Pharmacies Slash Prices for Wegovy and Mounjaro
Portfolio Pulse from Vandana Singh
In Britain, online pharmacies and slimming clinics are reducing prices for Novo Nordisk's Wegovy and Eli Lilly's Mounjaro due to easing supply shortages and increasing competition. This price reduction reflects the high demand for these weight-loss drugs. Despite the competitive pricing, concerns about patient care continuity persist. In Denmark, Novo Nordisk has lowered the price of its diabetes drug Ozempic following government subsidy restrictions. NVO shares dropped 4.02% to $124.02.
May 02, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's Mounjaro experiences price reductions in Britain amid growing competition and demand, affecting the company's revenue potential from this market.
The competitive pricing for Mounjaro in Britain, driven by high demand and competition among retailers, could potentially reduce Eli Lilly's revenue from this drug in the short term.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80
NEGATIVE IMPACT
Novo Nordisk's Wegovy sees price cuts in Britain due to increased competition and demand. In Denmark, Ozempic's price was reduced following subsidy restrictions, impacting the company's financials.
The price reduction in Britain for Wegovy and the subsidy restrictions in Denmark for Ozempic directly affect Novo Nordisk's revenue from these drugs. The reported share price drop of 4.02% indicates a negative short-term impact on NVO's stock.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90